Solventum Corporation SOLV
Verdict: Sell. Fair value $54.80 against a price of $83.32 on 6 Jan 2026, 34% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Net Income collapsed by 64.4% from $1.35B in 2023 to $0.48B in 2024, while revenue remained.... Operating Cash Flow (OCF) fell 38% from $1.92B in 2023 to $1.19B in 2024. While this is less severe....
Main risks
- Collapsing Cash Flow: TTM Free Cash Flow has plummeted to $50M from an average of $1.45B in the prior three fiscal years, with TTM OCF also showing severe deterioration. This is a major red flag for operational health.
- Extremely High Leverage: The capital structure is burdened with high debt, evidenced by a Debt/Equity ratio of 2.7x and a dangerously high Net Debt/EBITDA proxy of over 16x. This creates significant financial risk.
- Profitability Collapse: The TTM EBIT proxy is negative, and the most recent annual Net Income ($0.48B) is down ~65% from the prior 3-year average ($1.38B), indicating a severe contraction in profitability.
- Net Income collapsed by 64.4% from $1.35B in 2023 to $0.48B in 2024, while revenue remained...
- Operating Cash Flow (OCF) fell 38% from $1.92B in 2023 to $1.19B in 2024. While this is less severe...
- Intense competitive environment